Effects of Tyrosine Kinase Inhibitors on Liver Enzymes and Electrolytes

Assiut University

Status: Unknown

Conditions: Patients Diagnosed as Chronic Meyloid Leukemia

Treatments: Drug: Tyrosine kinase Inhibitors (Imatinib & Nilotinib)

Study type: Observational

Funder types: Other

Identifiers

NCT04326933

TKI In CML

Details and patient eligibility

About

Determine the effects of tyrosine kinase Inhibitors on liver enzymes and electrolytes in relation to hematologic response in patients with chronic phase chronic meyloid leukemia.. Assiut University Hospital insight..

Full description

CML is a myeloproliferative neoplasm with unique biological and clinical features.

CML accounts for 15_20% of newly diagnosed cases of leukemias among adults. CML can present in three clinical phases : chronic phase, accelerated phase and blast phase.

CML is characterized by prodction of a breakpoint cluster region abelson(BCR-ABL) fusion protein with ABL kinase activity. This is due to reciprocal translocation between chromosome 9 and 22.

Imatinib & Nilotinib, an ABL kinase inhibitors, which has revolutionized the CML therapy, are a selective tyrosine kinase inhibitors.

The aim of the study is to determine the changes of liver enzymes and electrolytes in relation to hematologic response during treatment period.

Enrollment: 40 estimated patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Newly diagnosed patients with CML
• Chronic phase CML
• Normal hepatic and renal functions

Exclusion criteria

• Blastic phase CML
• Accelerated phase CML
• Hepatic & renal impairment